The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Abstract
Purpose: Diverse immune-related effects occur with the use of epidermal growth factor receptor inhibitors (EGFRI). In addition to the cutaneous inflammation induced by EGFRIs, these agents have been associated with the exacerbation of autoimmune skin disease and contact hypersensitivity, antiviral effects, and fatal alveolar damage in the setting of lung transplantation. Because EGFR ligands can modulate MHC class I (MHCI) and II (MHCII) molecule expression, we hypothesized that some of the immune-related effects of EGFRIs are due to direct effects on the expression of MHCI and/or MHCII molecules. Experimental Design: Primary human keratinocytes and a malignant keratinocyte cell line (A431) were treated with EGFRIs alone or prior to IFN-γ, a potent inducer of MHCI and MHCII molecule expression. CIITA, MHCI, and MHCII RNA expression was measured using quantitative real-time reverse transcriptase PCR, and cell surface MHCI and MHCII protein expression was measured using flow cytometry. Skin biopsies from patients were analyzed for MHCI and MHCII protein expression before and during therapy with an EGFRI using immunohistochemistry. Results: Both EGFR tyrosine kinase inhibitors and ligand-blocking antibodies (cetuximab) augmented the induction of MHCI and MHCII molecules by IFN-γ in primary and malignant human keratinocytes. Unexpectedly, the increase in MHCI protein expression did not require the presence of IFN-γ. Consistent with these in vitro findings, skin biopsies from cancer patients exhibited increased epidermal MHCI protein expression during therapy with an EGFRI as well as increases in MHCI and MHCII molecule RNA. Conclusions: These studies suggest that EGFRIs may influence immune/inflammatory responses by directly modulating MHC expression. Clin Cancer Res; 17(13); 4400–13. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447
Induction of MHC Class I Expression by the MHC Class II Transactivator CIITA
Martin, B. K., Chin, K.-C., Olsen, J. C., Skinner, C. A., Dey, A., Ozato, K., & Ting, J. P.-Y. (1997) · Immunity · doi:10.1016/s1074-7613(00)80347-7 · Cited by 208
Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148
Cited by
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Drug resistance and new therapies in colorectal cancer
Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Metadata
- Authors
- Pollack, B. P., Sapkota, B., & Cartee, T. V.
- Venue
- Clinical Cancer Research
- Published
- 2011-07-01
- Volume
- 17
- Issue
- 13
- Pages
- 4400-4413
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2136799969
- Cited by
- 169
- References
- 3
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3283
- The paper
- Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011). Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3283
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.